What Solventum's FY2025 10-K says: 12 signals
Solventum filed its latest 10-K with the SEC on Feb 27, 2026. It discusses competitor named, restructuring and acquisition completed.
Public (SOLV)Outsourcing and Offshoring Consulting1,001 to 5,000 employeessolventum.comLinkedIn
- Filed
- Feb 27, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 10
What Solventum's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
Health Information Systems segment faces competition from Optum, Microsoft, Epic, and Oracle
Solventum's HIS business, which focuses on revenue cycle and clinician productivity software, operates in a highly competitive market against major HCIT players.
16.3%
Health Information Systems percentage of 2025 total sales
revenue cycle managementMicrosoftOracleOptum
MedSurg segment competes with Smith & Nephew, Medline, Cardinal Health, and Steris
The company's largest segment, MedSurg (57.9% of sales), faces significant competition in advanced wound care and surgical supplies markets.
57.9%
MedSurg percentage of 2025 total sales
Smith & NephewMedaxisMölnlyckeColoplast
Solventum faces challenges establishing standalone systems post-spin-off from 3M.
3M
Faces intense competition in HCIT from Microsoft, Oracle, Optum, and startups.
The Health Information Systems segment is being challenged by major tech players and disruptive startups in revenue cycle management and clinician productivity.
Microsoft (Nuance)Oracle (Cerner)OptumEpic
Solventum flags risk that systems are unprepared for standalone operations post-spinoff
As a new public company spun-off from 3M, Solventum's management warns that its accounting and other management systems may be inadequate.
3M
Solventum acquired bioscience company Acera Surgical in 2025
The acquisition of Acera Surgical expands Solventum's portfolio and market position.
Dental Solutions segment competes with Dentsply Sirona, Envista, and Align Technology
In the highly competitive dental and orthodontic market, Solventum competes with large multinational companies.
16.2%
Dental Solutions percentage of 2025 total sales
Dentsply SironaEnvistaStraumannIvoclar
Solventum identifies 3M as a sole-source supplier for critical raw materials post-spin-off.
This dependency on its former parent company, 3M, for raw materials in certain products creates a significant supply chain vulnerability.
3M
Company warns its accounting and management systems may be inadequate after spin-off.
As a new standalone public company, Solventum's existing systems may not be prepared to meet the financial reporting and other requirements.
Identifies 3M as a critical sole-source supplier, creating significant supply chain risk.
Solventum is dependent on its former parent company, 3M, as the sole source for certain raw materials.
3M
Showing 10 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Solventum with the Signal API
One POST /v1/companies/enrich call with solventum.com returns Solventum 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"solventum.com","signal_types":["sec-10k"],"limit":20}'Questions about Solventum 10-K
When did Solventum file its latest 10-K?
What does Solventum's latest 10-K say about competitor named?
Where can I find Solventum's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .